Types of Cancer We Treat

Prostate Cancer

Our nationally and internationally known specialists offer comprehensive services that include the most up-to-date, research-backed approaches to prostate cancer screening, diagnosis, treatment, post-treatment rehabilitation, and integrative therapies.

Our doctors share in the growing consensus among top prostate cancer specialists that many men are being overtreated for prostate cancer. We work together to identify which men are best served by aggressive treatment and which can be treated safely with a more conservative approach. We believe in empowering you with information, so that you can be an active partner in creating a personalized treatment plan that’s right for you.

Meet Our Doctors
Dr. Herbert Lepor
Diagnosis
Prostate Cancer Diagnosis
Active Surveillance
Prostate Cancer Active Surveillance
Surgery
Prostate Cancer Surgery
Radiation Therapy
Prostate Cancer Radiation Therapy
Minimally Invasive Ablation Treatment
Prostate Cancer Minimally Invasive Ablation Treatment
Hormone Therapies & Other Systemic Therapies
Prostate Cancer Hormone Therapies & Other Systemic Therapies

Related News

Navigating a Prostate Cancer Diagnosis
Read Story
Low-Risk Prostate Cancer Strategies for Veterans
Read Story
Surgery for Prostate Cancer Might Extend Longevity
Read Story
Don’t Always Trust Medical Information from Online Videos
Read Story
Metastatic Prostate Cancer Treatment Is Improving
Read Story
Encouraging Findings for Patients Undergoing Prostatectomy
Read Story
Deciding When to Treat Prostate Cancer
Read Story

Clinical Trials and Research Studies

Phase 1/2

A Parallel-Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1

Learn More

Phase N/A

PET/MRI (AXUMIN) STUDY OF MEN WITH HIGHLY SUSPICIOUS MRI LESIONS THAT SHOWED NO CLINICALLY SIGNIFICANT PROSTATE CANCER FOLLOWING MRI FUSION TARGETED BIOPSY

Learn More

Phase 3

PHASE III IGRT AND SBRT VS IGRT AND HYPOFRACTIONATED IMRT FOR LOCALIZED INTERMEDIATE RISK PROSTATE CANCER

Learn More

Phase 1

An Open-label Multicenter Phase 1b Study of JNJ-63723283 a PD-1 Inhibitor Administered in Combination with Apalutamide in Subjects with Metastatic Castration-Resistant Prostate Cancer

Learn More
View All Related Clinical Trials (13)